

# Immune Profiling for Cancer Immunotherapy Response

NCT06116032

---

**Status** RECRUITING  
**Sponsor** Dartmouth-Hitchcock Medical Center  
**Enrollment** 1,500 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
- Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).

### Exclusion (3)

- Pregnant women/fetuses/neonates
- Prisoners
- Decision-impaired individuals

## Locations (1 total)

---

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States